Kenvue bounces as Trump's Tylenol-autism link not backed by new scientific evidence
Shares of consumer health company Kenvue KVUE.N rise 6% to $17.99 premarket
Stock hit record low on Monday after President Donald Trump linked autism to childhood vaccine use and taking co's pain medication Tylenol by women when pregnant
Canaccord Genuity analysts say KVUE's risk is minimal and sell-off appears overblown, adding there is "more noise than substance"
Citi analysts say they expected the stock to recover, citing absence of new scientific evidence from the White House briefing
It is likely low-single-digit percentage of Tylenol sales come from use by pregnant women - Canaccord Genuity
On September 5, the Wall Street Journal reported that Health Secretary Robert F. Kennedy Jr. planned to link Tylenol to autism
Up to last close, stock fell 20.5% YTD
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
